Very little of Reyataz is (or was) prescribed unboosted. Used to be because patients could not tolerate ritonavir and had progressed from first line Sustiva. But that niche (second line NNRTI-resistant patients who can't tolerate ritonavir) is now gone to Isentress.
Market Data 
Markets 
AI
